NSC |
Compound |
Enrichment |
Correlation |
NSC 679021 |
Null |
0.0228506033927957 |
0.38509108 |
NSC 710525 |
Null |
0.0228506033927957 |
0.1474975 |
NSC 718530 |
Null |
0.0228506033927957 |
0.29142829 |
NSC 724784 |
(1S,4R,5R,8R,12R,13S)-1,5-dimethyl-9-methylene-11,14,15,16-t etraoxatetracyclo[10.3.1.04,13.08,13]hexadec-10-yl]oxy}-3-he xenyl)oxy]-1,5,-dimethyl-9-methylene-11,14,15,16-tetraoxatet racyclo[10.3.1.0 |
0.0228506033927957 |
0.3250927 |
NSC 740252 |
Null |
0.0228506033927957 |
0.33020068 |
NSC 669807 |
Null |
0.0260391472224205 |
0.40087074 |
NSC 732179 |
Null |
0.0260391472224205 |
0.11547567 |
NSC 750493 |
2-(2-hydroxyphenyl)-3-[5-(1H-imidazol-1-ylmethyl)-1,3,4-oxadiazol-2-yl]-1,3-thiazolidin-4-one |
0.0260391472224207 |
0.33765757 |
NSC 102225 |
Null |
0.0267520285931239 |
0.26165908 |
NSC 132791 |
Butyric acid, 2-hydroxy-2-methyl-, 4-ester with 1,3a.beta.,4,7,7a.alpha.,11,11a,11b.alpha.-octahydro-1.alpha.,2.alpha.,4.beta.,11.beta.-tetrahydroxy-3.alpha.,8,11a.beta.-trimethyl-2H-1,11c.beta.-(epo |
0.0267520285931239 |
0.31314384 |